ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 274 filers reported holding ARRAY BIOPHARMA INC in Q1 2019. The put-call ratio across all filers is 0.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,536,000 | +90.8% | 33,156 | +0.4% | 0.02% | +91.7% |
| Q1 2019 | $805,000 | +21.4% | 33,019 | -29.0% | 0.01% | +9.1% |
| Q4 2018 | $663,000 | +19.0% | 46,504 | +26.9% | 0.01% | +37.5% |
| Q3 2018 | $557,000 | -9.7% | 36,652 | -0.3% | 0.01% | -11.1% |
| Q2 2018 | $617,000 | – | 36,779 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |